Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194557 | 0.93 | BCL2L1 (0.43) | BCL2L1CXCR3CYP3A4PDE4BPDE4D | |
| SCHEMBL4190734 | 0.92 | PPARG (0.41) | TP53TRPV1POLBP2RY1PPARG | |
| SCHEMBL4187079 | 0.92 | PDE4B (0.41) | BCL2L1TP53POLBP2RY1PPARG | |
| SCHEMBL4187633 | 0.92 | PPARG (0.41) | TP53TRPV1POLBP2RY1PPARG | |
| SCHEMBL4183644 | 0.91 | TP53 (0.43) | TP53TRPV1POLBPPARGCXCR3 | |
| SCHEMBL4195071 | 0.90 | CNR2 (0.44) | TP53TRPV1POLBPPARGCXCR3 | |
| SCHEMBL4180891 | 0.89 | CXCR3 (0.44) | BCL2L1CXCR3CYP3A4PDE4BPDE4D | |
| SCHEMBL4187658 | 0.89 | POLB (0.47) | TP53TRPV1POLBPPARGMAPT | |
| SCHEMBL4183574 | 0.89 | TP53 (0.44) | TP53TRPV1POLBPPARGCXCR3 | |
| SCHEMBL4188348 | 0.88 | CNR2 (0.43) | BCL2L1TP53CXCR3CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1925617-B1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA PHARM CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-8193356-B2 | Heterocycle compound, and production process and application thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1925617-A1 | HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131467-A1 | Heterocycle Compound, and Production Process and Application Thereof | PDE3B, PDE4B, PDE7A | BCL2L1 4603/4885TP53 4856/4885TRPV1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.